207 related articles for article (PubMed ID: 25985626)
1. [Application of reprogramming technology for cancer research].
Yagi M; Semi K; Yamada Y
Nihon Rinsho; 2015 May; 73(5):751-5. PubMed ID: 25985626
[TBL] [Abstract][Full Text] [Related]
2. Induced pluripotent stem cell technology for dissecting the cancer epigenome.
Semi K; Yamada Y
Cancer Sci; 2015 Oct; 106(10):1251-6. PubMed ID: 26224327
[TBL] [Abstract][Full Text] [Related]
3. The Epigenetic Reprogramming Roadmap in Generation of iPSCs from Somatic Cells.
Brix J; Zhou Y; Luo Y
J Genet Genomics; 2015 Dec; 42(12):661-70. PubMed ID: 26743984
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation leading to induced pluripotency drives cancer development in vivo.
Ohnishi K; Semi K; Yamada Y
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):10-5. PubMed ID: 25019993
[TBL] [Abstract][Full Text] [Related]
5. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.
Ohnishi K; Semi K; Yamamoto T; Shimizu M; Tanaka A; Mitsunaga K; Okita K; Osafune K; Arioka Y; Maeda T; Soejima H; Moriwaki H; Yamanaka S; Woltjen K; Yamada Y
Cell; 2014 Feb; 156(4):663-77. PubMed ID: 24529372
[TBL] [Abstract][Full Text] [Related]
6. Cellular reprogramming and cancer development.
Semi K; Matsuda Y; Ohnishi K; Yamada Y
Int J Cancer; 2013 Mar; 132(6):1240-8. PubMed ID: 23180619
[TBL] [Abstract][Full Text] [Related]
7. Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells.
Hu C; Li L
Regen Med; 2016 Jan; 11(1):105-32. PubMed ID: 26679838
[TBL] [Abstract][Full Text] [Related]
8. Induced pluripotent stem cells reprogramming: Epigenetics and applications in the regenerative medicine.
Gomes KM; Costa IC; Santos JF; Dourado PM; Forni MF; Ferreira JC
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):180-189. PubMed ID: 28355380
[TBL] [Abstract][Full Text] [Related]
9. Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor.
Matsuda Y; Semi K; Yamada Y
Pathol Int; 2014 Jul; 64(7):299-308. PubMed ID: 25047500
[TBL] [Abstract][Full Text] [Related]
10. Obstacles in Renal Regenerative Medicine: Metabolic and Epigenetic Parallels Between Cellular Reprogramming and Kidney Cancer Oncogenesis.
Lichner Z; Mac-Way F; Yousef GM
Eur Urol Focus; 2019 Mar; 5(2):250-261. PubMed ID: 28847686
[TBL] [Abstract][Full Text] [Related]
11. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
Qi SD; Smith PD; Choong PF
ANZ J Surg; 2014 Jun; 84(6):417-23. PubMed ID: 24894037
[TBL] [Abstract][Full Text] [Related]
12. Integration-free reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) without viral vectors, recombinant DNA, and genetic modification.
Heng BC; Fussenegger M
Methods Mol Biol; 2014; 1151():75-94. PubMed ID: 24838880
[TBL] [Abstract][Full Text] [Related]
13. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
Qi SD; Smith PD; Choong PF
ANZ J Surg; 2014 Jun; 84(6):E1-11. PubMed ID: 23035845
[TBL] [Abstract][Full Text] [Related]
14. Generation of induced pluripotent stem cells from somatic cells.
Sohn YD; Han JW; Yoon YS
Prog Mol Biol Transl Sci; 2012; 111():1-26. PubMed ID: 22917224
[TBL] [Abstract][Full Text] [Related]
15. Induced pluripotent stem cell technology: trends in molecular biology, from genetics to epigenetics.
Maali A; Maroufi F; Sadeghi F; Atashi A; Kouchaki R; Moghadami M; Azad M
Epigenomics; 2021 Apr; 13(8):631-647. PubMed ID: 33823614
[TBL] [Abstract][Full Text] [Related]
16. Role of mass spectrometry-based proteomics in the study of cellular reprogramming and induced pluripotent stem cells.
Benevento M; Munoz J
Expert Rev Proteomics; 2012 Aug; 9(4):379-99. PubMed ID: 22967076
[TBL] [Abstract][Full Text] [Related]
17. Evolution of induced pluripotent stem cell technology.
Zhou H; Ding S
Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
[TBL] [Abstract][Full Text] [Related]
18. Current status in cancer cell reprogramming and its clinical implications.
Izgi K; Canatan H; Iskender B
J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
[TBL] [Abstract][Full Text] [Related]
19. The causal relationship between epigenetic abnormality and cancer development: in vivo reprogramming and its future application.
Yamada Y; Yamada Y
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(6):235-247. PubMed ID: 29887568
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation dynamics in human induced pluripotent stem cells.
Nishino K; Umezawa A
Hum Cell; 2016 Jul; 29(3):97-100. PubMed ID: 27083573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
